If for decades, the basic treatment of migraine has remained the same, new molecules that are original and specific to the migraine disease – acting on the CGRP pathway – have appeared. In France, the Transparency Commission issued favorable opinions on four anti-CGRP antibodies. What do these new molecules really bring? What benefits/risks? Why don’t patients benefit more?
